 WARREN, N.J., June 24, 2021 GLOBE NEWSWIRE -- Aquestive Therapeutics, Inc. NASDAQ: AQST, a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today the resubmission of its New Drug Application NDA to the U.S. Food and Drug Administration FDA for LibervantTM diazepam Buccal Film for the management of seizure clusters in response to the September 25, 2020 Complete Response Letter CRL from the FDA. The submission included additional statistical modeling and supporting analyses of the existing clinical data based upon the guidance received from the Agency. 